Sevelamer carbonate Winthrop 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IAIN/0034 
A.1 - Administrative change - Change in the name 
23/05/2023 
and/or address of the MAH 
IB/0033/G 
This was an application for a group of variations. 
04/04/2023 
SmPC, 
Labelling and 
PL 
SmPC, Annex 
II and PL 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
B.II.a.1.a - Change or addition of imprints, bossing 
or other markings including replacement, or addition 
of inks used for product marking - Changes in 
imprints, bossing or other markings 
B.II.b.1.e - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
B.II.d.1.z - Change in the specification parameters 
and/or limits of the finished product - Other variation 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.a.3.z - Changes in the composition (excipients) 
of the finished product - Other variation 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
B.II.b.4.b - Change in the batch size (including batch 
size ranges) of the finished product - Downscaling 
down to 10-fold 
B.II.b.2.c.2 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Including batch control/testing 
IB/0032/G 
This was an application for a group of variations. 
10/01/2023 
SmPC and PL 
Page 2/11 
 
 
 
 
 
 
 
 
 
B.II.e.2.b - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Addition of a new specification 
parameter to the specification with its corresponding 
test method 
B.II.e.2.b - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Addition of a new specification 
parameter to the specification with its corresponding 
test method 
B.II.b.1.e - Replacement or addition of a 
manufacturing site for the FP - Site where any 
manufacturing operation(s) take place, except batch-
release, batch control, primary and secondary 
packaging, for non-sterile medicinal products 
B.II.c.1.g - Change in the specification parameters 
and/or limits of an excipient - Where there is no 
monograph in the European/National Ph. for the 
excipient, a change in specification from in-house to 
a non-official/third country Ph. 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.d.1.c - Change in the specification parameters 
and/or limits of the finished product - Addition of a 
new specification parameter to the specification with 
its corresponding test method 
B.II.c.1.c - Change in the specification parameters 
and/or limits of an excipient - Deletion of a non-
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.II.b.3.a - Change in the manufacturing process of 
Page 3/11 
 
 
 
 
 
the finished or intermediate product - Minor change 
in the manufacturing process 
B.II.e.2.z - Change in the specification parameters 
and/or limits of the immediate packaging of the 
finished product - Other variation 
B.II.d.2.a - Change in test procedure for the finished 
product - Minor changes to an approved test 
procedure 
B.II.b.2.c.2 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Including batch control/testing 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
PSUSA/2697/
Periodic Safety Update EU Single assessment - 
10/06/2022 
n/a 
PRAC Recommendation - maintenance 
202110 
sevelamer 
IA/0031 
B.II.d.2.a - Change in test procedure for the finished 
13/04/2022 
n/a 
product - Minor changes to an approved test 
procedure 
IA/0030 
B.II.d.2.a - Change in test procedure for the finished 
18/02/2022 
n/a 
product - Minor changes to an approved test 
procedure 
N/0028 
Minor change in labelling or package leaflet not 
10/11/2021 
PL 
connected with the SPC (Art. 61.3 Notification) 
IA/0027/G 
This was an application for a group of variations. 
02/09/2021 
n/a 
Page 4/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A.7 - Administrative change - Deletion of 
manufacturing sites 
A.4 - Administrative change - Change in the name 
and/or address of a manufacturer or an ASMF holder 
or supplier of the AS, starting material, reagent or 
intermediate used in the manufacture of the AS or 
manufacturer of a novel excipient 
WS/1854 
This was an application for a variation following a 
12/11/2020 
12/11/2021 
SmPC, 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Labelling and 
PL 
C.I.z - Changes (Safety/Efficacy) of Human and 
Veterinary Medicinal Products - Other variation 
WS/1775 
This was an application for a variation following a 
17/04/2020 
n/a 
Removal of identified or potential risks from the list of 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.11.b - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated 
by new additional data to be submitted by the MAH 
where significant assessment is required 
C.I.11.b - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated 
by new additional data to be submitted by the MAH 
safety concerns as these risks are fully characterized and 
are followed up via routine pharmacovigilance. 
Page 5/11 
 
 
 
 
 
 
 
 
 
 
 
 
where significant assessment is required 
IA/0025 
A.5.b - Administrative change - Change in the name 
19/03/2020 
n/a 
and/or address of a manufacturer/importer of the 
finished product, including quality control sites 
(excluding manufacturer for batch release) 
N/0023 
Minor change in labelling or package leaflet not 
03/03/2020 
12/11/2021 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
R/0022 
Renewal of the marketing authorisation. 
19/09/2019 
11/11/2019 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Sevelamer carbonate Winthrop in the approved indication 
remains favourable and therefore recommended the 
renewal of the marketing authorisation with unlimited 
validity. 
PSUSA/2697/
Periodic Safety Update EU Single assessment - 
27/06/2019 
23/08/2019 
SmPC and PL 
Refer to Scientific conclusions and grounds recommending 
201810 
sevelamer 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/2697/201810. 
WS/1560 
This was an application for a variation following a 
16/05/2019 
23/08/2019 
SmPC, 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Labelling and 
PL 
B.IV.1.a.1 - Change of a measuring or administration 
device - Addition or replacement of a device which is 
not an integrated part of the primary packaging - 
Device with CE marking 
IA/0021 
A.7 - Administrative change - Deletion of 
23/04/2019 
23/08/2019 
Annex II and 
manufacturing sites 
PL 
Page 6/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0018/G 
This was an application for a group of variations. 
28/11/2018 
23/08/2019 
SmPC, 
A.1 - Administrative change - Change in the name 
and/or address of the MAH 
A.2.a - Administrative change - Change in the 
(invented) name of the medicinal product for CAPs 
Labelling and 
PL 
X/0011 
Annex I_2.(c) Change or addition of a new 
26/07/2018 
20/09/2018 
SmPC, 
strength/potency 
N/0017 
Minor change in labelling or package leaflet not 
25/07/2018 
20/09/2018 
connected with the SPC (Art. 61.3 Notification) 
Labelling and 
PL 
PL 
PSUSA/2697/
Periodic Safety Update EU Single assessment - 
14/06/2018 
n/a 
PRAC Recommendation - maintenance 
201710 
sevelamer 
WS/1383 
This was an application for a variation following a 
07/06/2018 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
B.II.f.1.e - Stability of FP - Change to an approved 
stability protocol 
IG/0926/G 
This was an application for a group of variations. 
06/06/2018 
n/a 
A.7 - Administrative change - Deletion of 
manufacturing sites 
B.I.b.1.d - Change in the specification parameters 
and/or limits of an AS, starting 
material/intermediate/reagent - Deletion of a non-
Page 7/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
significant specification parameter (e.g. deletion of 
an obsolete parameter) 
B.I.c.1.a - Change in immediate packaging of the AS 
- Qualitative and/or quantitative composition 
WS/1332 
This was an application for a variation following a 
22/02/2018 
20/09/2018 
SmPC and PL 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Update of sections 4.2 and 6.6 of the SmPC in order 
to include the use of food and beverage as an 
alternative to water for administration of sevelamer 
carbonate powder for oral suspension. 
The Package Leaflet is updated accordingly. 
In addition, the Worksharing applicant (WSA) took 
the opportunity to revise the Annex A. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
N/0012 
Minor change in labelling or package leaflet not 
15/12/2017 
20/09/2018 
Labelling and 
connected with the SPC (Art. 61.3 Notification) 
PL 
IG/0844 
C.I.11.a - Introduction of, or change(s) to, the 
22/09/2017 
20/09/2018 
SmPC, 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
wording agreed by the competent authority 
Labelling and 
PL 
IG/0804/G 
This was an application for a group of variations. 
26/06/2017 
n/a 
Page 8/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B.I.a.2.a - Changes in the manufacturing process of 
the AS - Minor change in the manufacturing process 
of the AS 
B.I.a.3.a - Change in batch size (including batch size 
ranges) of AS or intermediate - Up to 10-fold 
increase compared to the originally approved batch 
size 
WS/0965 
This was an application for a variation following a 
18/05/2017 
23/06/2017 
SmPC and PL 
Please refer to the Scientific Discussion of Renvela and 
Sevelamer carbonate Zentiva EMEA/H/C/WS0965. 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Extension of indication for Renvela 1.6 g and 2.4 g 
powder for oral suspension and Sevelamer carbonate 
Zentiva 2.4 g powder for oral suspension to include 
the control of hyperphosphataemia in paediatric 
patients (>6 years of age and a Body Surface Area 
(BSA) of >0.75 m2) with chronic kidney disease. As 
a consequence, sections 4.2, 4.8 and 5.1 of the 
SmPC are updated in order to add information on 
posology and safety in paediatric patients and to 
reflect the results of the paediatric study. 
The Package Leaflet is updated in accordance. 
C.I.6.a - Change(s) to therapeutic indication(s) - 
Addition of a new therapeutic indication or 
modification of an approved one 
PSUSA/2697/
Periodic Safety Update EU Single assessment - 
09/06/2017 
n/a 
PRAC Recommendation - maintenance 
201610 
sevelamer 
Page 9/11 
 
 
 
 
 
 
 
 
 
 
 
PSUSA/2697/
Periodic Safety Update EU Single assessment - 
23/06/2016 
18/08/2016 
SmPC 
Refer to Scientific conclusions and grounds recommending 
201510 
sevelamer 
the variation to terms of the Marketing Authorisation(s)’ for 
PSUSA/2697/201510. 
WS/0867 
This was an application for a variation following a 
11/02/2016 
18/08/2016 
SmPC and PL 
Changes in gastric acidity with acid suppressants may 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
Update of section 4.5 of the SmPC regarding drug-
drug interaction between sevelamer and proton 
pump inhibitors. The Package Leaflet has been 
updated accordingly. In addition, the MAH took the 
opportunity to implement editorial changes in section 
4.8 of the SmPC of Renvela and Sevelamer 
carbonate Zentiva in order to harmonize the wording 
for all Sevelamer compounds. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
WS/0803 
This was an application for a variation following a 
19/11/2015 
n/a 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.11.b - Introduction of, or change(s) to, the 
obligations and conditions of a marketing 
authorisation, including the RMP - Implementation of 
change(s) which require to be further substantiated 
by new additional data to be submitted by the MAH 
where significant assessment is required 
potentially alter the efficacy of sevelamer HCL. During post-
marketing experience, very rare cases of increased 
phosphate levels have been reported in patients taking 
proton pump inhibitors co-administered with sevelamer 
hydrochloride. 
Page 10/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
WS/0770 
This was an application for a variation following a 
01/10/2015 
11/02/2016 
SmPC and PL 
worksharing procedure according to Article 20 of 
Commission Regulation (EC) No 1234/2008. 
C.I.4 - Change(s) in the SPC, Labelling or PL due to 
new quality, preclinical, clinical or pharmacovigilance 
data 
IB/0002 
B.II.e.5.a.2 - Change in pack size of the finished 
09/04/2015 
11/02/2016 
SmPC, 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change outside 
the range of the currently approved pack sizes 
Labelling and 
PL 
IAIN/0001 
B.II.a.1.a - Change or addition of imprints, bossing 
17/02/2015 
11/02/2016 
SmPC and PL 
or other markings including replacement, or addition 
of inks used for product marking - Changes in 
imprints, bossing or other markings 
Page 11/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
